DUPIXENT® (dupilumab) Sitemap

Rate your conversation

< !-- modal-header -->

< !-- form-group -->

🙁😐😃🤩

< !-- form-group -->

< !-- modal-body -->

Thanks for the feedback !

< !-- modal-content -->

< !-- modal-dialog -->

For U.S. Healthcare
Professionals Only
Prescribing
Information
- PRESCRIBING INFORMATION
- Prescribing Information - English
- Prescribing Information - Spanish
- PRE-FILLED SYRINGE INSTRUCTIONS FOR USE
- 200 mg Dose - English
- 200 mg Dose - Spanish
- 300 mg Dose - English
- 300 mg Dose - Spanish
- PRE-FILLED PEN INSTRUCTIONS FOR USE
- 200 mg Dose - English
- 200 mg Dose - Spanish
- 300 mg Dose - English
- 300 mg Dose - Spanish
Visit Patient Site
Contact a Rep

Moderate-to-Severe
Atopic Dermatitis

Moderate-to-Severe Asthma
(EOS/OCS-Dependent)
Chronic Rhinosinusitis
with Nasal Polyposis
Eosinophilic Esophagitis
Prurigo Nodularis
DUPIXENT HCP Homepage

ABOUT
DUPIXENT
EFFICACY AND
SAFETY
- ADULT (18+ YEARS)
  
  Efficacy and Safety Overview
  
  Study Designs
  
  Peak Pruritus NRS
  Efficacy Results
  
  IGA Efficacy Results
  
  EASI Efficacy Results
  
  Real-world Results
  
  Safety Profile
  ADOLESCENT
  (12-17 YEARS)
  
  Study Design
  
  Peak Pruritus NRS
  Efficacy Results
  
  IGA Efficacy Results
  
  EASI Efficacy Results
  
  Safety Profile
  CHILDREN
  (6-11 YEARS)
  
  Study Design
  
  Peak Pruritus NRS
  Efficacy Results
  
  IGA Efficacy Results
  
  EASI Efficacy Results
  
  Safety Profile
  INFANTS TO PRESCHOOLERS
  (6 months-5 years)
  
  Study Design
  
  Worst Scratch/Itch NRS Efficacy Results
  
  IGA Efficacy Results
  
  EASI Efficacy Results
  
  Safety Profile
DOSAGE AND
ADMINISTRATION
PATIENT SUPPORT
PROGRAM
resources
- Resource Library
- Formulary Coverage
Visit Patient Site

Sitemap

SITE MAP

Dupixent Home
About DUPIXENT
Overview
Real-world Results
Dosage and Administration
Resources
- Resource Library
Contact a Rep

Important Safety Information

Important Safety
Information and Indications

CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT versus placebo, with conjunctivitis being the most frequently reported eye disorder. Conjunctivitis also occurred more frequently in chronic rhinosinusitis with nasal polyposis subjects and prurigo nodularis subjects who received DUPIXENT compared to those who received placebo. Conjunctivitis and keratitis have been reported with DUPIXENT in postmarketing settings, predominantly in AD patients. Some patients reported visual disturbances (e.g., blurred vision) associated with conjunctivitis or keratitis. Advise patients to report new onset or worsening eye symptoms to their healthcare provider. Consider ophthalmological examination for patients who develop conjunctivitis that does not resolve following standard treatment or signs and symptoms suggestive of keratitis, as appropriate.

Eosinophilic Conditions: Patients being treated for asthma may present with serious systemic eosinophilia sometimes presenting with clinical features of eosinophilic pneumonia or vasculitis consistent with eosinophilic granulomatosis with polyangiitis (EGPA), conditions which are often treated with systemic corticosteroid therapy. These events may be associated with the reduction of oral corticosteroid therapy. Healthcare providers should be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients with eosinophilia. Cases of eosinophilic pneumonia were reported in adult subjects who participated in the asthma development program and cases of vasculitis consistent with EGPA have been reported with DUPIXENT in adult subjects who participated in the asthma development program as well as in adult subjects with co-morbid asthma in the CRSwNP development program. A causal association between DUPIXENT and these conditions has not been established.

Acute Asthma Symptoms or Deteriorating Disease: Do not use DUPIXENT to treat acute asthma symptoms, acute exacerbations, acute bronchospasm or status asthmaticus. Patients should seek medical advice if their asthma remains uncontrolled or worsens after initiation of DUPIXENT.

Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Patients with Co-morbid Asthma: Advise patients with co-morbid asthma not to adjust or stop their asthma treatments without consultation with their physicians.

Arthralgia: Arthralgia has been reported with the use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Advise patients to report new onset or worsening joint symptoms. If symptoms persist or worsen, consider rheumatological evaluation and/or discontinuation of DUPIXENT.

Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves. Helminth infections (5 cases of enterobiasis and 1 case of ascariasis) were reported in pediatric patients 6 to 11 years old in the pediatric asthma development program.

Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines in patients treated with DUPIXENT.

ADVERSE REACTIONS:

Atopic Dermatitis: The most common adverse reactions (incidence ≥1%) in patients are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia. The safety profile in pediatric patients through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT ± TCS in pediatric patients observed through Week 52 was consistent with that seen in adults with atopic dermatitis, with hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation.
Asthma: The most common adverse reactions (incidence ≥1%) are injection site reactions, oropharyngeal pain, and eosinophilia.
Chronic Rhinosinusitis with Nasal Polyposis: The most common adverse reactions (incidence ≥1%) are injection site reactions, eosinophilia, insomnia, toothache, gastritis, arthralgia, and conjunctivitis.
Eosinophilic Esophagitis: The most common adverse reactions (incidence ≥2%) are injection site reactions, upper respiratory tract infections, arthralgia, and herpes viral infections.
Prurigo Nodularis: The most common adverse reactions (incidence ≥2%) are nasopharyngitis, conjunctivitis, herpes infection, dizziness, myalgia, and diarrhea.

USE IN SPECIFIC POPULATIONS

Pregnancy: A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1‑877‑311‑8972 or go to https://mothertobaby.org/ongoing-study/dupixent/. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

Please see accompanying full Prescribing Information.

Indications

Atopic Dermatitis: DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

Asthma: DUPIXENT is indicated as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.

Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP):
DUPIXENT is indicated as an add-on maintenance treatment in adult patients with inadequately controlled CRSwNP.

Eosinophilic Esophagitis: DUPIXENT is indicated for the treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis (EoE).

Prurigo Nodularis: DUPIXENT is indicated for the treatment of adult patients with prurigo nodularis (PN).

References:

DUPIXENT Prescribing Information.
Data on file, Regeneron Pharmaceuticals, Inc.
Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282-1293.
EASI User Guide. HOME–Harmonising Outcome Measures for Eczema. Accessed March 11, 2020. www.homeforeczema.org/documents/easi-user-guide-jan-2017-v3.pdf
Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353-1357.

Site Map
Legal Disclaimer Information

Questions or comments?
Contact Sanofi US or call 1-844-643-7346
to contact Regeneron Pharmaceuticals, Inc.

© 2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
DUPIXENT® and DUPIXENT MyWay® are registered trademarks of Sanofi Biotechnology.

DUP.22.12.0128 Last Update: May 2023

Sanofi US is hosting this website on behalf of Sanofi and Regeneron Pharmaceuticals, Inc.

Sanofi and Regeneron are industry partners, who are committed to handling personal data in ways that respect your privacy. Both companies may independently process your personal data to manage patient support programs and product marketing campaigns. Please refer to Regeneron’s Privacy Notice and Sanofi’s Privacy Policy for more information regarding processing of your personal data.

Are you sure you want to leave?

Please note: By clicking on this link, you will be leaving this Sanofi-hosted US website and going to another, entirely independent website. Sanofi US and Regeneron provide these links as a service to their website visitors and users; however, they take no responsibility for the information on any website but their own.

Are you sure you want to leave?

Please note: By clicking on this link, you will be leaving this Sanofi-hosted US website and going to another, entirely independent website. Sanofi US and Regeneron provide these links as a service to their website visitors and users; however, they take no responsibility for the information on any website but their own.

US-DAS-1231(1)

Enter your email address and we will send you your requested resource.

Email Address Please provide a valid email address.

Success!

Your email is on its way. Be sure to check your inbox.